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We examined the in vitro anti-human immunodeficiency virus (HIV) activity of MRN-100, an
iron-based compound derived from bivalent and tervalent ferrates. MRN-100 action against
HIV-1 (SF strain) was tested in primary cultures of peripheral blood mononuclear cells (MNC)
by analyzing p24 antigen production and percent survival of MNC infected with HIV. MRN-
100 at a concentration of 10% (v/v) inhibited HIV-1 replication in 11 out of 14 samples (79%).
The percentage of suppression of p24 antigen was 12.3 to 100% at 10 days post-treatment.
MRN-100 also exhibited a significant protective effect in the survival of HIV-1-infected MNC.
MNC survival post-treatment was dose dependent, 70.4%8.4, 83.6%10.7 and 90%11.4,
at concentrations 2.5, 5 and 10% (v/v), respectively, as compared with 53%4 for HIV-1-
infected MNC without treatment. The effect was detected as early as 4 days and continued up
to 11 days. Treatment with MRN-100 caused no significant change in proliferative response of
MNC alone or cocultured with different mitogens: PHA and Con-A (activators of T cell
function) and PWM (activator of CD4
+ T cell-dependent B cells). We concluded that MRN-
100 possesses anti-HIV activity in vitro and without an increase in lymphocyte proliferation,
MRN-100 may be a useful agent for treating patients with acquired immunodeficiency
syndrome.
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Introduction
Human immunodeficiency virus (HIV) is the causative
agent of the acquired immunodeficiency syndrome (AIDS).
HIV is one of the principle threats to human life and health
worldwide. More than 25 million people have died and an
estimated 39 million were living with HIV by the year 2005.
A complex relationship exists between HIV and its cellular
targets. An increase in immunodeficiency and the transi-
tion to AIDS is marked by a decrease in the number of
CD4
+ T lymphocytes as HIV exerts its cytolytic effect on
these cells (1,2). However, as is the case with other
Lentiviruses, the macrophage is also a major target cell
for the HIV virus. Furthermore, the macrophage appears
to be a more stable host, and is considered to be the
primary reservoir for the virus in the host (3). CD4
molecules are not restricted to T cells but are also found on
other cells (4–8). Therefore, infection by HIV-1 is also
characterized by a disregulation of the immune system,
which results in increased susceptibility to opportunistic
infections, and increased frequency of certain neoplasmas
(9–13). Another feature of HIV infection is anemia.
Castaldo et al. (14) reported iron deficiency in 48% of
HIV-infected children. In addition, Rosseau et al. (15)
reported iron deficiency in 19% of adult HIV patients; they
also noted nosignificant difference in the iron level between
patients with CD4
+ cell counts <250/mm
3 and patients
with CD4
+ cells counts >250/mm
3. HAART treatment
For reprints and all correspondence: Mamdooh Ghoneum, Ph.D.,
Department of Otolaryngology, Charles R. Drew University of
Medicine and Science, 1621 E. 120th Street, Los Angeles, CA 90059,
USA. Tel: +323-563-5953; Fax: +310-474-6724;
E-mail: mghoneum@ucla.edu
*Data presented at the Palm Springs Symposium on HIV/AIDS,
Foundation of HIV Therapy, Palm Springs, CA. March 13–16, 1997.
 2008 The Author(s).
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original worki s
properly cited.did not change the level of iron as compared with non-
HAART patients.
HAART is a frequent choice for first-line therapy
that consists of a combination of protease inhibitors,
nucleoside reverse transcriptase inhibitors and/or non-
nucleoside reverse transcriptase inhibitors. Other
HAART treatments that have proven immensely potent
in the therapy of AIDS are Lopinavir/ritonavir (LPV/r)
and tenofovir disoproxil fumarate (TDF). However,
HAART, LPV/r and TDF all are expensive and cause
severe side effects (16). Therefore, there is much interest
and need to identify anti-HIV agents with minimal side
effects, which are also affordable.
It is of great interest to note that iron ions possess anti-
viral activity against several viruses, such as Junin virus,
herpes simplex virus and several bacteriophages (17). In
addition, iron ions inactivate HIV in vitro, as indicated
by inhibition of the syncytial formation and the synthesis
of virus-specific p24 antigen in HIV–infected cells (18).
Current research for the use of iron in the development
of a new anti-AIDS drug is underway. Several com-
pounds including iron ions with anti-HIV activity have
been reported, such as ferrocene (Fe(II)(C5H5)2), an
organometallic chemical compound (19), and ferrovir,
a trivalent iron in complex with native sturgeon milt
DNA (20,21). The present study was undertaken to
investigate the in vitro anti-HIV activity of MRN-100,
which is obtained from the plant extract phytosin. MRN-
100 is an iron-based compound derived from bivalent
and tervalent ferrates and sold as a beverage in Japan.
Results of this study demonstrated that MRN-100
inhibited HIV replication in peripheral blood mono-
nuclear cells (MNC) in vitro without cytotoxicity.
Material and Methods
MRN-100
MRN-100 is an iron-based compound derived from
bivalent and tervalent ferrates and was prepared in
distilled water (DW) with the concentration of Fe
2+
and Fe
3+ ions at 210
12mol/l. MRN-100 is obtained
from phytosin, a plant extract that contains iron and
neutral lipid compounds and is found in rice, wheat or
radish seeds. When phytosin is dispersed in DW, ferric
chloride is added, the lipid compounds are removed and
the iron compound thus obtained is subjected to
fractional determination with respect to bivalent ferrate
and tervalent ferrate in order to generate MRN-100.
MRN-100 was provided by ACM Co., Ltd., Japan.
Complete Medium (CM)
The CM consists of RPMI-1640 (Sigma, St. Louis, MO,
USA) supplemented with 10% (v/v) fetal bovine serum
and 100mg/ml streptomycin and penicillin.
Preparation of Peripheral Blood MNCs
MNCs were prepared from heparinized peripheral venous
blood by Ficoll-Hypaque density gradient centrifugation.
Blood (20ml) was gently overlaid on the surface of 6ml
Ficoll-Hypaque and centrifuged at 1400rpm for 45min;
then the buffy coat which contained MNCs was aspirated
using Pasteur pipette. The cells were washed twice with
Hanks balance salt solution (HBSS) and resuspended in
serum-free AIM V medium (GIBCO, Long Island, NY).
Production of HIV-1 p24 Antigen
MNCs from 14 healthy individuals were incubated with
5mg/ml of PHA for 3 days (37C) and then washed
before incubation (37C, 1h) with HIV-1 SF strain
(HIV-1 p24 of 3000pg/10
6 cells). MNCs were then
washed 3x with PBS to remove unbound viruses before
incubation (37C, 10 days) either with or without MRN-
100 at concentration of 10% (v/v) in CM. Half of the
medium was changed twice per week with corresponding
MRN-100 concentrations. Another set of experiments
was carried out to evaluate proper controls such as AZT
(1nmol/ml) for comparison. At the end of the incubation
period (10 days), culture supernatants of HIV-infected-
cells were collected and analyzed for viral production.
HIV-1 p24 antigen was assayed using a commercially
available ELISA kit, (DuPont NEN, Boston, MA, USA)
according to manufacturer’s protocol.
MNCs Survival
MNCs survival was determined using a colorimetric
MTT assay. This assay is based on the reduction of
tetrazolium salt MTT [3-(4,5-dimethylthiozol-3-yl)-2,
5-diphenyltetrazolium bromide] by a mitochondrial dehy-
drogenase in viable cells from a colorless to a blue-
colored formazan product that can be measured spectro-
metrically. The amount of formazan produced is propor-
tional to the number of living cells. HIV-1 infected cells
(110
4/well) were seeded in 96-well plates and cultured
in triplicate in the presence or absence of MRN-100 at
various concentrations 0–10% (v/v). A control group of
MNC neither infected with HIV nor treated with MRN-
100 was included. The final volume of medium in each
well after addition of MRN-100 was 200ml. The cultures
were incubated at 37C for 3 days, after which 50mgo f
MTT was added to each well and the cultures incubated
for an additional 4h. The plates were centrifuged, the
medium carefully removed, the formazan crystals solubi-
lized with acid alcohol and the plates read at 590nm
using an ELISA plate reader (Molecular Devices, Menlo
Park, CA, USA).
Cell Viability
Cell viability was measured using the propidium iodide
technique and FACScan (Becton-Dickinson, San Jose,
428 MRN-100 possesses anti-HIV activityCA, USA). Briefly, MNCs were infected with HIV-1 and
incubated in the presence of MRN-100 at various
concentrations; 2.5, 5 and 10% (v/v). A control group
of MNC neither infected with HIV nor treated with
MRN-100 was included. At the end of incubation period
(11 days), MNCs were stained with propidium iodide
(5mg/ml) for 30min. Ten-thousand cells were acquired
and analyzed with CellQuest software (Becton
Dickinson). Experiments were done in triplicate with
data expressed as percent viable cells.
T and B Lymphocyte Proliferation
We investigated the in vitro effects of MRN-100 on T and
B cell proliferation as well as mitogen-induced prolifera-
tion, using
3H-thymidine uptake. MNCs (210
5 cells/ml)
from six healthy individuals were treated with 10mg/ml
of one of the following mitogens: phytohemagglutinin
(PHA), Concavalin A (Con A) or pokeweed mitogen
(PWM) in the presence or absence of MRN-100 at
concentration of 10% (v/v) for 3 days. One mCi of
3H-thymidine (New England Nuclear) was added to the
cell cultures during the last 18h. DNA was harvested and
3H-thymidine uptake was determined by scintillation
counter. All experiments were done in triplicate and
data expressed as counts per minute (cpm).
Statistical Analysis
For the percentage of MNC cell survival and the percent
change of p24 antigen suppression, we analyzed the data
using the Wilcoxon signed ranks test and the sign test to
assess the significant differences between the groups. The
survival related variables data were analyzed using a one-
way analysis of variance (ANOVA) to test the hypothesis
that the means of the groups are equal. We used the post
hoc range tests and pair-wise multiple comparisons to
determine which means differ. Pair-wise multiple
comparisons test the difference between each pair of
means, and yield a matrix where we identified the
significantly different group means at an alpha level of
0.05. We used the multiple comparison tests, Bonferroni
test and also detected the least significance difference
between the groups using the LSD (least significant
difference). The data were analyzed using SPSS software
version 15.
Results
Production of HIV-1 p24 Antigen
p24 antigen production was examined in MNC from 14
different HIV-1 infected samples that were treated with
MRN-100 at a concentration of 10% (v/v) for 10 days
(Fig. 1). The Wilcoxon signed ranks test showed a
significant inhibition (P=0.002) of HIV p24 antigen
production between the MRN-100 group and the control
group (MNC without MRN-100). A clear differential
response can be seen among different individuals towards
inhibitory effects by MRN-100. The percentage of
suppression of p24 antigen for all samples was 12.3 to
100%: 100% suppression in four samples, 40–70% in
four samples, 12–23% in three samples, no significant
change in two samples and 10% increase in one sample.
With respect to the control, data shows that treatment
with AZT resulted in zero percent of p24 antigen
production. Regarding the percent change of p24 antigen
production, we had two groups: one group represented
the percent of p24 suppression of the MRN-100 relative
to the control group and the second group represented
Figure 1. Inhibition of HIV-1 p24 antigen production by MRN-100. Data from 14 different samples were examined at 10 days post-treatment with
MRN-100 in triplicate. AZT (1nmol/ml) was used as a control. The data represents meanSD of triplicate counts for each sample.
eCAM 2010;7(4) 429the percent of p24 suppression of the MRN-100 relative
to the AZT group. The Wilcoxon signed ranks test
showed a statistically significant difference between the
two groups (P=0.001).
MNC Survival and Cell Viability
Effect of MRN-100 on the survival of HIV-1 infected
MNCs was determined by MTT assay and the data is
depicted in Figs 2 and 3. A control group of MNC
neither infected with HIV nor treated with MRN-100 was
included, and experimental values were normalized to this
control. P-values reflected a comparison to the control
group (Fig. 2). Results show that infection with HIV-1
resulted in 50% MNC survival. Treatment with MRN-
100 increased survival of HIV-infected MNC in a dose
dependent manner. MRN-100 at a concentration of 2.5%
(v/v) significantly increased MNC survival to 70% as
compared with the control group. Higher concentrations,
5 and 10% (v/v), resulted in a significant increase of cell
survival, as compared with the HIV-infected group
without MRN-100 treatment. The increase in the survival
of HIV-infected cells was noted at 4, 7 and 11 days post-
treatment with MRN-100.
The effect of MRN-100 on the viability of HIV-1
infected cells was examined. Results in Fig. 4 show no
significant change in the viability of the HIV-1 infected
cells post-treatment with MRN-100 up until 11 days
post-infection as compared with the control group of
MNC neither infected with HIV nor treated with
MRN-100.
Effect of MRN-100 on T and B Cell Proliferation
MNC from six healthy samples were cultured with
MRN-100 for 3 days and cell proliferation was examined.
Fig. 5A shows treatment with MRN-100 resulted in a
slight elevation in cell proliferation at different concen-
trations [2.5–10% (v/v)] as compared with control
untreated cells. Fig. 5B shows that MRN-100 at
concentration of 10% (v/v) caused no significant change
in proliferative response of MNC cocultured with
different mitogens: PHA and ConA (T cell function
activators) and PWM (B cell activator).
Figure 3. Percent survival of HIV-1 infected MNC post-treatment with
MRN-100 in vitro. MNC infected cells were cultured with MRN-100 at
different concentrations (v/v): 0% (filled diamond), 2.5% (filled square),
5% (filled triangle) and 10% (filled circle). Percent survival of MNC was
examined at 4, 7 and 11 days. Data are expressed as meanSD of three
samples carried in triplicate relative to a control group that was neither
infected with HIV nor treated with MRN-100, which was set as 100%.
Figure 2. In vitro action of MRN-100 on the survival of HIV-1 infected
MNC. MNC were infected with HIV-1 and cultured with MRN-100 at
concentrations of 0–10% (v/v). Survival of MNC was examined at 4, 7
and 11 days by MTT assay. Data are expressed as meanSD of three
samples in triplicate. OD, optical density. *P<0.0001, **P=0.01
and P=0.02 (open circle) as compared with the control group (C)
(no HIV-1 and no MRN-100 treatment). P<0.01 (filled diamond),
P=0.005 (open square) and P<0.001 (open diamond) as compared
with the HIV-infected group.
Figure 4. Effect of MRN-100 on cell viability. MNCs from six samples
were infected with HIV-1 and incubated in the presence of MRN-100 at
the various concentrations, 2.5, 5 and 10% (v/v), for 11 days. Cell
viability was measured with the propidium iodide technique using
FACScan. Experiments were done in triplicate with data expressed as
percent viable cells. Results were compared with the control group of
MNC neither infected with HIV nor treated with MRN-100.
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The results of this study showed that MRN-100, an iron-
based compound derived from bivalent and tervalent
ferrates, caused a significant increase in the survival of
HIV-1 infected MNC and inhibition of p24 antigen
production without an adverse affect on lymphocyte
functions. Recently, there has been much research on the
role of iron ions in anti-HIV activity. Sagripanti and
Lightfoote reported that ferric ions inactivate HIV when
cells are infected with the virus and when the virus was
free in solution (18). da Silva et al. (19) and Nossik et al.
(20,21) have shown that ferrovir and ferrocene inhibit
HIV replication. Our results are in agreement with the
above studies, and taken together, suggest that iron based
compounds may provide an effective complementary and
alternative treatment for subjects infected with HIV virus.
The use of complementary and alternative medicine
(CAM) for the treatment of HIV is becoming more
common in the USA (22,23), Canada (24) and Europe
(25). For CAM in relation to HAART, studies in the
USA revealed that CAM therapies complement, rather
than replace, HAART (26). In Canada, nearly all
patients used CAM in conjunction with antiretroviral
medications (24), while in Europe the patients were
administered CAM after reporting HAART-related side
effects (25). Several studies indicate that many CAM
therapies may improve the quality of life of people living
with HIV-AIDS (26–28); on the other hand, the
effectiveness of CAM against HIV is inconclusive (29).
Clearly, further investigations on CAM therapies are
needed to prove their effectiveness both with respect to
clinical and basic research settings. Recent studies show
that several CAM therapies have anti-HIV activity in
vitro. Polysaccharides from different sources such as
those found in rice bran (arabinoxylan) (30), pine cones
(Pinus parvifloria Sieb Zucc) (31) and the plant Hyssop
officinalis (32) inhibit the production of HIV antigen in
HIV-infected MNC. A phase II controlled study of a
combination of lentinan, beta-glucans from the Shiitake
mushroom (Lentinula edodes), with the antiviral drug
didanosine (DDI) was carried out in HIV patients.
A significant increase in CD4 levels was observed post-
treatment with this combination (38 weeks) when
compared with DDI alone (14 weeks) (33).
The mechanisms by which MRN-100 inactivates HIV-1
are not fully understood. Sagripanti and Lightfoote (18)
reported complete inhibition in the formation of syncytia
and synthesis of virus-specific p24 antigen in HIV-
infected cells post-treatment with Fe
3+. Ferrovir (20,21)
has been shown to influence DNA and RNA synthesis
during early stages of HIV-1 replication by blocking the
virus’ action on cell metabolism. Ferrocene has been
reported to inhibit the activity of integrase, and thus
block integration and subsequent viral replication. It is
possible that both cellular and viral enzymes may be the
targets for MRN-100 action. Alternatively, MRN-100
may exert its anti-HIV activity via NK immune modula-
tion. AIDS is associated with abnormalities in NK cell
function (11,12). Moreover, NK cells may play a role in
host depletion of HIV-1 infected cells (34,35). In this
regard, preliminary studies show that MRN-100 activates
NK activity of healthy control samples in vivo (36).
Adverse side effects are one of the problems with using
anti-HIV agents for treatment. Prolonged use of several
anti-HIV drugs is associated with severe toxicity and
development of drug resistance (37,38). MRN-100 is a
beverage that is sold in Japan. In vitro studies have
demonstrated that MRN-100 has no suppressive effect on
lymphocyte function. In conclusion, we propose that
MRN-100 possesses anti-HIV activity in vitro, indicating
that it may be a useful agent for treating patients with
AIDS.
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